Premium
Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma
Author(s) -
Sheng Yuanyuan,
Wei Jinwang,
Zhang Yu,
Gao Xiaomei,
Wang Zheng,
Yang Jing,
Yan Shican,
Zhu Ying,
Zhang Ze,
Xu Da,
Wang Chaoqun,
Zheng Yan,
Dong Qiongzhu,
Qin Lunxiu
Publication year - 2019
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.31979
Subject(s) - metastasis , eph receptor a2 , cancer research , intrahepatic cholangiocarcinoma , medicine , lymphatic system , exome sequencing , cancer , biology , pathology , receptor tyrosine kinase , oncology , mutation , receptor , gene , genetics
Exploring the genetic aberrations favoring metastasis is important for understanding and developing novel strategies to combat cancer metastasis. It remains lack of effective treatment for the dismal prognosis of intrahepatic cholangiocarcinoma (ICC). Here, we aimed to study genetic alternations during lymph node metastasis of ICC and investigate potential mechanisms and clinical strategy focused on mutations. We performed whole‐exome sequencing and transcriptome sequencing on samples from 30 ICC patients, including lymph node metastases from five of the patients. We identified the alterations of genetic pattern related to lymph node metastases of ICC. EPHA2, a member of the tyrosine kinase family, was found to be frequently mutated in ICC. Correlation analysis indicated that EPHA2 mutations were closely associated with lymph node metastasis of ICC. In vitro and in vivo experiments revealed that EPHA2 mutations could lead to ligand independent phosphorylation of Ser897, and promote lymphatic metastasis of ICC, in which NOTCH1 signaling pathway played an important role. In both in vitro assays and patient‐derived xenografts, an inhibitor of Ser897 phosphorylation effectively suppressed the metastasis of ICC with mutated EPHA2. Our findings demonstrated that EPHA2 mutants may be an attractive therapeutic target for lymphatic metastasis of ICC.